- $677.97m
- $625.73m
- $73.24m
- 99
- 16
- 86
- 75
Annual balance sheet for Iradimed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 52 | 62.5 | 58 | 49.8 | 52.2 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4.57 | 5.14 | 13.3 | 12.2 | 10.6 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 63.7 | 76.2 | 77.5 | 76 | 75.2 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4.84 | 4.55 | 4.61 | 11.3 | 17 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 71.1 | 82.9 | 85.5 | 92.2 | 98.3 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.92 | 6.82 | 8.55 | 16.3 | 8.51 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 9.68 | 10.7 | 11.8 | 20.7 | 11.5 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 61.4 | 72.2 | 73.7 | 71.4 | 86.8 |
Total Liabilities & Shareholders' Equity | 71.1 | 82.9 | 85.5 | 92.2 | 98.3 |
Total Common Shares Outstanding |